The 3Q24 results are slightly above our expectations on the back of an improved operating margin. The guidance of EUR 1.15 EPRA EPS is reiterated. Home invest is one of the best performers to date among Belgian REITs. However, in the last month there was profit taking and negative news on regulation. As of 01/11/2024, rent increases in Brussels (66% portfolio) are on hold for 9 consecutive years. This was already the case for the 3-6-9 contracts but now impacts short term contracts and tenant de...
We raise our TP to € 23.4 and switch our rating back to Outperform on FLOW. The reason for our upgrade is two-fold. In the short-term, we expect the US elections (5 November) to lead to higher market volatility and volume growth, these being the main ingredients for revenue generation. Over the medium term however, we see a path for FLOW to structurally grow its trading capital organically at a 15% CAGR, reaching € 1bn by FY 2027. - - >Upgrading to Outperform on US electio...
Aalberts: 3Q24 preview - no signs of recovery expected. AB InBev: All to play for in the final quarter. Arcadis: A mixed bag. Ayvens: Struggling to get out of neutral. dsm-firmenich: Taking your vitamins is healthy. D'Ieteren: Belron equity at €23.5bn, EV €32.2bn in minority shareholder transaction. Euronext: 3Q24 and CMD Preview. Flow Traders: Bumper harvest. Heijmans: 3Q24 as expected, keeps FY outlook in place. Proximus: Key politician pushing for major governance shake up. ...
>Results above expectations, driven by dislocations in equities in EU and APAC - FLOW came out with a strong set of Q3 figures this morning, which were materially above consensus expectations. Group NTI came in at € 107.3m, 27% above expectations, and implying a strong QoQ acceleration of 35%. Strong performance was recorded across all regions. EBITDA margin was 44.1%, a beat of 11p.p to consensus, given the rather fix cost nature of the business resulting in strong o...
We measured the impact of the contribution from Michel Barnier’s exceptional tax on 88 stocks exposed to France. Some 17 of them would experience a (negative) impact on their EPS of more than 4% on average over 2024 and 2025: LDC (-8.3%), Synergie (-8%), Eiffage (-7.9%), ADP (-7.9%), Dassault Aviation (-7%), Crit (-6.9%), Derichebourg (-6.3%), Hermès (-5.6%), Safran (-5.6%), Bouygues (-5.6%), M6 (-5.2%), Thales (-5%), TF1 (-4.9%), Nexans (-4.9%), Vinci (-4.7%), Compagnie des Alpes (...
Nous avons mesuré l’impact de la contribution exceptionnelle Barnier sur 88 valeurs exposées à la France. 17 d’entre elles auraient un impact (négatif) sur leurs BPA de plus de 4% en moyenne sur 2024 et 2025 : LDC (-8,3%), Synergie (-8%), Eiffage (-7,9%) ADP (-7,9%), Dassault Aviation (-7%), Crit (-6,9%), Derichebourg (-6,3%), Hermès (-5,6%), Safran (-5,6%), Bouygues (-5,6%), M6 (-5,2%), Thalès (-5%), TF1 (-4,9%), Nexans (-4,9%), Vinci (-4,7%), Compagnie des Alpes (-4,4%), FDJ (-4%). - ...
>Miss on a weaker than expected Entertainment - This morning Barco released a slightly weak set of results, with revenues below ccs and our estimates. Estimates for Entertainment were too positive. As repeatedly flagged by the company, while the comparison base is improving, several end markets (mainly in EMEA) are still showing subdued activity and customers postponing purchases awaiting for new product introductions impacted Q3 24 performance as well. This resulted ...
3Q24 orders and sales were below our and CSS forecasts with main underperformance in Entertainment. Although Barco sees gradual recovery, led by the Healthcare division and the Americas region, while market conditions in EMEA remain challenging, we already lower our Target Price to € 14.2 (was € 15.8). We (and CSS) will have to lower our forecasts as Barco now expects a topline in 2H24 around the level of last year (previously it was “topline growth in the second half”).
Hyloris reported preliminary 1H24 results with total revenues of € 4.6m (1H23: € 2.3m), which include a € 2.1m milestone payment for the launch of Maxigesic IV in the US. While a specific cash runway was not provided, the company believes it's well capitalised to fund R&D for existing products, but will require additional funding to commercialise its near-term cardiology products in the US. We reiterate our € 5 TP and Hold rating.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.